J
James Campbell
Researcher at Institute of Cancer Research
Publications - 64
Citations - 4531
James Campbell is an academic researcher from Institute of Cancer Research. The author has contributed to research in topics: Olaparib & Gene. The author has an hindex of 28, co-authored 61 publications receiving 3657 citations. Previous affiliations of James Campbell include University of Bradford & King's College London.
Papers
More filters
Journal ArticleDOI
Proteome-based plasma biomarkers for Alzheimer's disease
Abdul Hye,Steven Lynham,Madhav Thambisetty,Mirsada Causevic,James Campbell,Helen Byers,Claudie Hooper,Fruhling Rijsdijk,Sarah J. Tabrizi,Steven J. Banner,Christopher Shaw,C. Foy,Michaela Poppe,Nicola Archer,Gillian Hamilton,John Powell,Richard G. Brown,Pak C. Sham,Malcolm Ward,Simon Lovestone +19 more
TL;DR: It is suggested that blood may be a rich source for biomarkers of Alzheimer's disease and that complement factor H, together with other proteins such as alpha-2M, May be a specific markers of this illness.
Journal ArticleDOI
Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease
Madhav Thambisetty,Andrew Simmons,Latha Velayudhan,Abdul Hye,James Campbell,Yi Zhang,Lars-Olof Wahlund,Eric Westman,Anna Kinsey,Andreas Güntert,Petroula Proitsi,John Powell,Mirsada Causevic,Richard Killick,Katie Lunnon,Steven Lynham,Martin Broadstock,Fahd Choudhry,David R. Howlett,Robert J. Williams,Sally I. Sharp,Cathy Mitchelmore,Catherine Tunnard,Rufina Leung,Catherine Foy,Darragh O'Brien,Gerome Breen,Simon J. Furney,Malcolm Ward,Iwona Kłoszewska,Patrizia Mecocci,Hilkka Soininen,Magda Tsolaki,Bruno Vellas,Angela Hodges,Declan G. Murphy,Sue Parkins,Jill C. Richardson,Susan M. Resnick,Luigi Ferrucci,Dean F. Wong,Yun Zhou,Sebastian Muehlboeck,Alan C. Evans,Paul T. Francis,Christian Spenger,Simon Lovestone +46 more
TL;DR: These results demonstrate an important role of clusterin in the pathogenesis of AD and suggest that alterations in amyloid chaperone proteins may be a biologically relevant peripheral signature of AD.
Journal ArticleDOI
Genome-wide profiling of genetic synthetic lethality identifies CDK12 as a novel determinant of PARP1/2 inhibitor sensitivity.
I. Bajrami,J. Frankum,Asha Konde,Rowan E. Miller,Farah L. Rehman,Rachel Brough,James Campbell,David Sims,R. Rafiq,Sean D. Hooper,Lina Chen,Iwanka Kozarewa,Ioannis Assiotis,Kerry Fenwick,Rachael Natrajan,Christopher J. Lord,Alan Ashworth +16 more
TL;DR: In models of high-grade serous ovarian cancer (HGS-OVCa), CDK12 attenuation was sufficient to confer sensitivity to PARP1/2 inhibition, suppression of DNA repair via homologous recombination, and reduced expression of BRCA1.
Journal ArticleDOI
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor.
Louise J. Barber,Shahneen Sandhu,Lina Chen,James Campbell,Iwanka Kozarewa,Kerry Fenwick,Ioannis Assiotis,Daniel Nava Rodrigues,Jorge S. Reis-Filho,Victor Moreno,Joaquin Mateo,L Rhoda Molife,Johann S. de Bono,Stan B. Kaye,Christopher J. Lord,Alan Ashworth +15 more
TL;DR: Massively parallel DNA sequencing of treatment‐naive and post‐olaparib treatment biopsies identified tumour‐specific BRCA2 secondary mutations in olaparir‐resistant metastases, which most likely cause olapsarib resistance by re‐establishing BRC a2 function in the tumour cells.
Journal ArticleDOI
Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance
Stephen J. Pettitt,Dragomir B. Krastev,Inger Brandsma,Amy Dréan,Feifei Song,Radoslav Aleksandrov,Maria I. Harrell,Malini Menon,Rachel Brough,James Campbell,Jessica Frankum,Michael Ranes,Helen Pemberton,Rumana Rafiq,Kerry Fenwick,Amanda Swain,Sebastian Guettler,Jung-Min Lee,Elizabeth M. Swisher,Stoyno S. Stoynov,Kosuke Yusa,Alan Ashworth,Christopher J. Lord +22 more
TL;DR: It is found that PARP1 mutations are tolerated in BRCA1 mutated cells, suggesting alternative resistance mechanisms and reinforces the importance of trappedPARP1 as a cytotoxic DNA lesion and suggests that PARp1 intramolecular interactions might influence PARPi-mediated cytotoxicity.